SEC Comment Letter 0000000000-26-001315 to Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc.
Date: Feb. 9, 2026 · CIK: 0001708599 · Accession: 0000000000-26-001315
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293107
Letter
February 9, 2026 Steven Ledger Chief Executive Officer Serina Therapeutics, Inc. 601 Genome Way, Suite 2001 Huntsville, AL 35806 Re:Serina Therapeutics, Inc. Registration Statement on Form S-3 Filed January 30, 2026 File No. 333-293107 Dear Steven Ledger: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Stephen Hinton
Show Raw Text
February 9, 2026
Steven Ledger
Chief Executive Officer
Serina Therapeutics, Inc.
601 Genome Way, Suite 2001
Huntsville, AL 35806
Re:Serina Therapeutics, Inc.
Registration Statement on Form S-3
Filed January 30, 2026
File No. 333-293107
Dear Steven Ledger:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Stephen Hinton